

Hans de reu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7238442/publications.pdf>

Version: 2024-02-01

11
papers

233
citations

1163117

8
h-index

1281871

11
g-index

13
all docs

13
docs citations

13
times ranked

449
citing authors

#	ARTICLE	IF	CITATIONS
1	Transpresentation of interleukin-15 by IL-15/IL-15R α mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity. <i>Oncotarget</i> , 2015, 6, 44123-44133.	1.8	39
2	Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion. <i>Frontiers in Immunology</i> , 2018, 9, 658.	4.8	38
3	Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion. <i>Cancer Immunology Research</i> , 2017, 5, 710-715.	3.4	36
4	Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing. <i>Frontiers in Immunology</i> , 2018, 9, 2503.	4.8	29
5	Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. <i>Journal of Translational Medicine</i> , 2022, 20, 124.	4.4	21
6	Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA. <i>Journal of Neuroinflammation</i> , 2019, 16, 167.	7.2	20
7	A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches. <i>Oncotarget</i> , 2018, 9, 27797-27808.	1.8	17
8	Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA. <i>Cancers</i> , 2020, 12, 256.	3.7	12
9	Preexisting memory CD4 T cells in naïve individuals confer robust immunity upon hepatitis B vaccination. <i>ELife</i> , 2022, 11, .	6.0	11
10	Engineering of regulatory T cells by means of mRNA electroporation in a GMP-compliant manner. <i>Cytotherapy</i> , 2022, , .	0.7	4
11	Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands. <i>Frontiers in Immunology</i> , 2022, 13, 734256.	4.8	2